Latest & greatest articles for Sibutramine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Sibutramine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Sibutramine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Sibutramine

1. Cardiac arrest caused by sibutramine obtained over the Internet: a case of a young woman without pre‐existing cardiovascular disease successfully resuscitated using extracorporeal membrane oxygenation (PubMed)

Cardiac arrest caused by sibutramine obtained over the Internet: a case of a young woman without pre‐existing cardiovascular disease successfully resuscitated using extracorporeal membrane oxygenation Sibutramine is a weight loss agent that was withdrawn from the market in the USA and European Union because it increases adverse events in patients with cardiovascular diseases. However, non-prescription weight loss pills containing sibutramine can be still easily purchased over the Internet.A (...) 21-year-old woman without history of cardiovascular diseases developed cardiac arrest. She was a user of a weight loss pills, containing sibutramine and hypokalemia-inducing agents, imported from Thailand over the Internet.She was successfully resuscitated without any neurological deficits by using extracorporeal membrane oxygenation for refractory ventricular fibrillation.This case indicates that sibutramine can cause cardiac arrest even in subjects without pre-existing cardiovascular disease

Full Text available with Trip Pro

2017 Acute medicine & surgery

2. Influence of sibutramine in addition to diet and exercise on the relationship between weight loss and blood glucose changes. (PubMed)

Influence of sibutramine in addition to diet and exercise on the relationship between weight loss and blood glucose changes. Weight loss is expected to improve glycaemic control in patients with diabetes or at high risk hereof. Sibutramine causes weight loss and is associated with an increased risk of myocardial infarction and stroke in high-risk patients. We examined the impact of sibutramine-induced weight loss on glycaemic control.In total, 8192 obese patients with diabetes were randomized (...) to sibutramine or placebo plus diet and exercise after a preliminary 6 weeks in which all patients received sibutramine. Patients were classified into four groups of weight change. A total of 1582 patients had a weight loss >5.7 kg; 2047 patients lost 3.7-5.7 kg; 2432 patients lost <3.7 kg, and 1875 patients gained weight. Patients on sibutramine lost slightly more weight than those on placebo (-0.2 kg on average, P < 0.0001). Mean blood glucose changes in the placebo group were -0.6 mmol/L (±3.1, P = 0.0002

Full Text available with Trip Pro

2016 European heart journal. Cardiovascular pharmacotherapy Controlled trial quality: uncertain

3. Sibutramine

Sibutramine USE OF SIBUTRAMINE IN PREGNANCY 0344 892 0909 USE OF SIBUTRAMINE IN PREGNANCY (Date of issue: August 2015 , Version: 1.1 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . Summary Sibutramine is a drug used for the treatment of obesity. It affects the appetite control centre in the brain by inhibiting (...) the reuptake of the neurotransmitters noradrenaline and serotonin. In general, weight loss should not be attempted during pregnancy. There are limited published data on the effects of sibutramine in human pregnancy. There is concern about a possible association between weight loss in overweight women in early pregnancy and neural tube defects in the offspring based on data from studies on other appetite suppressants with similar modes of action. No evidence of teratogenicity was seen in animal studies

2014 UK Teratology Information Service

4. Systematic review of the clinical efficacy of sibutramine and orlistat in weight loss, quality of life and its adverse effects in obese adolescents

Systematic review of the clinical efficacy of sibutramine and orlistat in weight loss, quality of life and its adverse effects in obese adolescents Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

5. Sibutramine: suspension of EU licences recommended

Sibutramine: suspension of EU licences recommended Sibutramine: suspension of EU licences recommended - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Sibutramine: suspension of EU licences recommended Evidence indicates risks outweigh benefits. Published 11 December 2014 From: Therapeutic area: Article date: February 2010 The European Medicines Agency (EMA) has completed a review of the obesity medicine sibutramine (Reductil) on the basis of new safety information from a large (...) clinical trial, the Sibutramine Cardiovascular OUTcomes (SCOUT) study. The review has found that the cardiovascular risks of sibutramine outweigh its benefits. The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended suspension of the licences for this medicine across the European Union. SCOUT was a randomised, double-blind, placebo controlled study in approximately 10 000 obese and overweight patients with cardiovascular disease and/or type 2 diabetes treated over a 6-year

2010 MHRA Drug Safety Update

6. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis

Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

7. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. (PubMed)

Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established.We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management (...) with and without sibutramine in subjects at high risk for cardiovascular events. All the subjects received sibutramine in addition to participating in a weight-management program during a 6-week, single-blind, lead-in period, after which 9804 subjects underwent random assignment in a double-blind fashion to sibutramine (4906 subjects) or placebo (4898 subjects). The primary end point was the time from randomization to the first occurrence of a primary outcome event (nonfatal myocardial infarction, nonfatal

Full Text available with Trip Pro

2010 NEJM Controlled trial quality: predicted high

8. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis

Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

9. Orlistat and sibutramine beyond weight loss

Orlistat and sibutramine beyond weight loss Orlistat and sibutramine beyond weight loss Orlistat and sibutramine beyond weight loss Mannucci E, Dicembrini I, Rotella F, Rotella C M CRD summary This review aimed to assess the effects of orlistat and sibutramine on blood lipids. It concluded that orlistat, but not sibutramine, determined a significant reduction in total cholesterol independent of the weight loss itself. Important information on the methods was missing from the review, so (...) it was impossible to determine whether the conclusions were reliable. Authors' objectives To assess the effects of orlistat and sibutramine on blood lipids independent of weight loss. Searching MEDLINE was searched from inception to the end of May 2005 for relevant English-language articles. Search terms were reported. The reference lists of identified trials and review articles were searched to identify further relevant evidence. Study selection Randomised, double-blind, placebo-controlled trials of six to 12

2008 DARE.

10. Review: dietary plus pharmacological intervention (orlistat or sibutramine) induces long term weight loss in overweight or obese adults

Review: dietary plus pharmacological intervention (orlistat or sibutramine) induces long term weight loss in overweight or obese adults Review: dietary plus pharmacological intervention (orlistat or sibutramine) induces long term weight loss in overweight or obese adults | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please (...) see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: dietary plus pharmacological intervention (orlistat or sibutramine) induces long term weight loss in overweight

2007 Evidence-Based Nursing

11. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. (PubMed)

Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Antiobesity treatment is recommended for selected patients in whom lifestyle modification is unsuccessful. Two antiobesity drugs are currently licensed for long-term use. Orlistat, a gastrointestinal lipase inhibitor, reduces weight by around 3 kg on average and decreases progression to diabetes in high-risk patients; adverse gastrointestinal effects are common. Sibutramine, a monoamine-reuptake inhibitor, results in mean

2007 Lancet

12. The cost-effectiveness of sibutramine in non-diabetic obese patients: evidence from four Western countries

The cost-effectiveness of sibutramine in non-diabetic obese patients: evidence from four Western countries Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.

13. Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes

Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes Article Text Therapeutics Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes Free Christopher

Full Text available with Trip Pro

2006 Evidence-Based Medicine (Requires free registration)

14. Review: orlistat and sibutramine are modestly effective for weight loss at 1 year

Review: orlistat and sibutramine are modestly effective for weight loss at 1 year Review: orlistat and sibutramine are modestly effective for weight loss at 1 year | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: orlistat and sibutramine are modestly effective for weight loss at 1 year Article Text Therapeutics Review: orlistat and sibutramine are modestly effective for weight loss at 1 year Free Christopher D Byrne , FRCP

Full Text available with Trip Pro

2006 Evidence-Based Medicine (Requires free registration)

15. Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany

Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany Brennan A, Ara R, Sterz R, Matiba B, Bergemann R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined a 1-year course of sibutramine in combination with diet and lifestyle advice for the treatment of obese patients. Sibutramine was initially given at a dosage of 10 mg/day but could be switched to 15 mg/day in the case of non-response at 1 or 3 months. Type

2006 NHS Economic Evaluation Database.

16. Cost-effectiveness of sibutramine in the LOSE Weight Study: evaluating the role of pharmacologic weight-loss therapy within a weight management program

Cost-effectiveness of sibutramine in the LOSE Weight Study: evaluating the role of pharmacologic weight-loss therapy within a weight management program Cost-effectiveness of sibutramine in the LOSE Weight Study: evaluating the role of pharmacologic weight-loss therapy within a weight management program Cost-effectiveness of sibutramine in the LOSE Weight Study: evaluating the role of pharmacologic weight-loss therapy within a weight management program Malone D C, Raebel M A, Porter J A, Lanty F (...) A, Conner D A, Gay E C, Merenich J A, Vogel E A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of sibutramine in conjunction with a weight management programme (WMP) for the treatment of overweight and obese individuals

2005 NHS Economic Evaluation Database.

17. Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies

Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies Vettor R, Serra R, Fabris R, Pagano C, Federspil G CRD summary This review assessed the effects of sibutramine on weight and glycaemic (...) control in obese patients with type 2 diabetes mellitus. The authors concluded that sibutramine may help to improve glycaemic control because it reduces weight. Inadequate reporting of the quality assessment, characteristics of the included studies, drop-outs and some review methods makes interpretation of the evidence difficult. Authors' objectives To assess the effects of sibutramine on weight and glycaemic control in obese people with type 2 diabetes mellitus. Searching The Cochrane Library

2005 DARE.

18. The efficacy and safety of sibutramine for weight loss: a systematic review

The efficacy and safety of sibutramine for weight loss: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 DARE.

19. Cost-effectiveness of sibutramine in the treatment of obesity

Cost-effectiveness of sibutramine in the treatment of obesity Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 NHS Economic Evaluation Database.

20. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. (PubMed)

Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. Adolescent obesity is becoming a national public health problem. Weight-loss medications including sibutramine facilitate weight control in adults and could be used with obese adolescents in combination with behavior therapy (BT).To examine whether increased weight loss in obese adolescents is induced when sibutramine is added to a family-based, behavioral weight control program.Randomized (...) , double-blind, placebo-controlled trial consisting of 82 adolescents aged 13 to 17 years with a body mass index (BMI) of 32 to 44 conducted from March 1999 to August 2002 at a university-based clinic for 6 months, followed by open-label treatment during months 7 to 12.For the first 6 months, participants received either BT and sibutramine or BT and placebo. From months 7 to 12, all participants received sibutramine in open-label treatment.Percentage change in BMI; systolic and diastolic blood pressure

Full Text available with Trip Pro

2003 JAMA Controlled trial quality: predicted high